BioCryst Pharmaceuticals, Inc.
BCRX
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930ā¦ read more
Healthcare
Biotechnology
31 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$7.70
Price+2.26%
$0.17
1Y
Price
Market Cap
$1.621b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years+20.2%
EBITDA Margin+8.1%
Net Profit Margin+25.0%
Free Cash Flow MarginRevenue
$599.816m
+33.1%
1y CAGR+30.5%
3y CAGR+40.9%
5y CAGREarnings
-$8.779m
+90.1%
1y CAGR+53.1%
3y CAGR+31.2%
5y CAGREPS
-$0.05
+88.4%
1y CAGR+54.4%
3y CAGR+33.5%
5y CAGRBook Value
-$387.889m
$446.424m
Assets$834.313m
Liabilities$683.109m
DebtDebt to Assets
153.0%
8.1x
Debt to EBITDAFree Cash Flow
$47.342m
+189.1%
1y CAGR+91.6%
3y CAGR+65.5%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company